Aevi Genomic Medicine (GNMX) Reports ASCEND Trial (Parts A & B) of AEVI-001 in Children with ADHD 'Did Not Achieve Statistical Significance on Primary Endpoint'

January 2, 2019 4:36 PM
Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) ("the Company") today announced that the ASCEND trial, a genomically-guided Phase 2 double-blind, placebo-controlled ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot Corp. News Hot FDA News Management Comments Trading Halts

Next Articles